Metastatic prostatic carcinoma which is sensitive to androgen-deprivation therapy.
Related
100 Clinical Results associated with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Login to view more data
100 Translational Medicine associated with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Login to view more data
0 Patents (Medical) associated with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Login to view more data
6
Literatures (Medical) associated with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
01 Feb 2023·Urologie (Heidelberg, Germany)
Neue S3-Leitlinie Prostatakarzinom 2021 (Version 6.2) – Was hat sich beim fortgeschrittenen Prostatakarzinom geändert?
Review
Author: Thomas, C ; Schrader, A J
01 Dec 2022·Aktuelle Urologie
Osteoprotektion beim nichtmetastasierten hormonsensitiven Prostatakarzinom (nmHSPC) unter androgendeprivativer Therapie (ADT): Aktuelle Daten aus Deutschland, vorgelegt von d-uo
Article
Author: Nitz, Christian ; Eichenauer, Rolf ; Jaeger, Andreas ; Brenneis, Horst ; König, Frank ; Fieseler, Claus ; Romagnolo, Allesandro ; Burkert-Scholz, Marcus ; Hempel, Elke ; Beuke, Maike ; Schröder, Jörg ; Klier, Jörg ; Doehn, Christian ; Johannsen, Manfred ; Binder, Manfred ; Reese, Stephan ; Schönfelder, Robert
01 Feb 2022·Aktuelle UrologieQ4 · MEDICINE
Aktuelle Entwicklungen in der Therapielandschaft des metastasierten hormonsensitiven Prostatakarzinoms (mHSPC)
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.